Terms: = Prostate cancer AND ATM, TELO1, 472, ENSG00000149311, TEL1, ATD, ATE, DKFZp781A0353, AT1, Q13315, MGC74674, ATDC, ATC, ATA AND Staging
6 results:
1. Identification of Genes with Rare Loss of Function Variants Associated with Aggressive prostate cancer and Survival.
Saunders EJ; Dadaev T; Brook MN; Wakerell S; Govindasami K; Rageevakumar R; Hussain N; Osborne A; Keating D; Lophatananon A; Muir KR; ; Darst BF; Conti DV; Haiman CA; Antoniou AC; Eeles RA; Kote-Jarai Z
Eur Urol Oncol; 2024 Apr; 7(2):248-257. PubMed ID: 38458890
[TBL] [Abstract] [Full Text] [Related]
2. prostate cancer: Under-representation of African American Men in Research Studies Used in the Latest NCCN Guidelines.
Lubarsky R; Ambinder D; Barnett J; Choudhury M; Saji A; Fishman AI; Fullerton S; Phillips JL
Urology; 2023 Oct; 180():28-34. PubMed ID: 37479145
[TBL] [Abstract] [Full Text] [Related]
3. Diabetes and beta-adrenergic blockage are risk factors for metastatic prostate cancer.
Krönig M; Haverkamp C; Schulte A; Heinicke L; Schaal K; Drendel V; Werner M; Wetterauer U; Schultze-Seemann W; Jilg CA
World J Surg Oncol; 2017 Feb; 15(1):50. PubMed ID: 28222734
[TBL] [Abstract] [Full Text] [Related]
4. Metallothionein - immunohistochemical cancer biomarker: a meta-analysis.
Gumulec J; Raudenska M; Adam V; Kizek R; Masarik M
PLoS One; 2014; 9(1):e85346. PubMed ID: 24416395
[TBL] [Abstract] [Full Text] [Related]
5. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer.
Ishkanian AS; Zafarana G; Thoms J; Bristow RG
Acta Oncol; 2010 Oct; 49(7):888-94. PubMed ID: 20590366
[TBL] [Abstract] [Full Text] [Related]
6. Differential HMGA expression and post-translational modifications in prostatic tumor cells.
Diana F; Di Bernardo J; Sgarra R; Tessari MA; Rustighi A; Fusco A; Giancotti V; Manfioletti G
Int J Oncol; 2005 Feb; 26(2):515-20. PubMed ID: 15645138
[TBL] [Abstract] [Full Text] [Related]
